My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hemostemix Inc (OP:HMTXF)

0.0703 +0.0023 (+3.38%)
Streaming Delayed Price Updated: 12:15 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hemostemix Inc

Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for September 18th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... 
Via Newsfile
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... 
Via Newsfile
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 16, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is... 
Via Newsfile
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to... 
Via Newsfile
Topics Intellectual Property
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased... 
Via Newsfile
Hemostemix Announces Its Presentation to the Emerging Growth Conference
Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")... 
Via Newsfile
Topics Economy Intellectual Property
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
Calgary, Alberta--(Newsfile Corp. - September 13, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased... 
Via Newsfile
Hemostemix Announces Closing of $2,750,000
Hemostemix Announces Closing of $2,750,000 - IssueWire 
Via IssueWire
Topics Intellectual Property
Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed
Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed - IssueWire 
Via IssueWire
Topics Intellectual Property Lawsuit
Your Fountain of Youth Trademarked by Hemostemix Inc.
Your Fountain of Youth Trademarked by Hemostemix Inc. - IssueWire 
Via IssueWire
Topics Intellectual Property
Hemostemix Announces Closing of UNIT Private Placement
Hemostemix Announces Closing of UNIT Private Placement - IssueWire 
Via IssueWire
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
Photo by Chris Montgomery on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
Calgary, Alberta--(Newsfile Corp. - September 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased... 
Via Newsfile
Topics Economy Intellectual Property
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
Calgary, Alberta--(Newsfile Corp. - July 6, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company")... 
Via Newsfile
Topics Economy Intellectual Property
Peter Lacey Increases His Investment in Hemostemix Inc.
Calgary, Alberta--(Newsfile Corp. - June 21, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company")... 
Via Newsfile
Topics Intellectual Property
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - June 11, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased... 
Via Newsfile
Topics Economy Intellectual Property
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
Calgary, Alberta--(Newsfile Corp. - April 23, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO.F) ("Hemostemix" or the "Company")... 
Via Newsfile
Topics Economy Intellectual Property
Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.
Calgary, Alberta--(Newsfile Corp. - April 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0.F) ("Hemostemix" or the... 
Via Newsfile
Topics Economy Intellectual Property
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.